Millennium Management LLC decreased its position in shares of Integra lifesciences (NASDAQ:IART) by 21.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,689 shares of the life sciences company’s stock after selling 4,311 shares during the period. Millennium Management LLC’s holdings in Integra lifesciences were worth $751,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of IART. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Integra lifesciences by 38.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after acquiring an additional 1,054 shares in the last quarter. Campbell Newman Asset Management Inc. grew its stake in Integra lifesciences by 21.5% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock worth $333,000 after buying an additional 1,234 shares during the last quarter. Stone Ridge Asset Management LLC purchased a new position in Integra lifesciences during the 4th quarter worth approximately $360,000. Virtu Financial LLC purchased a new position in Integra lifesciences during the 4th quarter worth approximately $378,000. Finally, Fox Run Management L.L.C. purchased a new position in Integra lifesciences during the 4th quarter worth approximately $388,000. 89.68% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have weighed in on IART. BidaskClub upgraded Integra lifesciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 8th. Oppenheimer set a $70.00 price target on Integra lifesciences and gave the company a “buy” rating in a report on Tuesday, May 1st. ValuEngine raised Integra lifesciences from a “sell” rating to a “hold” rating in a report on Friday, April 27th. Zacks Investment Research raised Integra lifesciences from a “hold” rating to a “buy” rating and set a $69.00 price objective for the company in a report on Tuesday, May 1st. Finally, Morgan Stanley lifted their price objective on Integra lifesciences from $53.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, April 26th. Eleven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $59.23.
In other news, Director Keith Bradley sold 15,658 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $55.00, for a total transaction of $861,190.00. Following the completion of the sale, the director now owns 37,074 shares in the company, valued at approximately $2,039,070. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel L. Reuvers sold 1,000 shares of the stock in a transaction on Monday, April 30th. The shares were sold at an average price of $62.04, for a total value of $62,040.00. The disclosure for this sale can be found here. Insiders have sold 80,765 shares of company stock valued at $4,376,248 over the last ninety days. Corporate insiders own 5.10% of the company’s stock.
Integra lifesciences opened at $64.09 on Friday, Marketbeat Ratings reports. Integra lifesciences has a one year low of $63.13 and a one year high of $63.52. The stock has a market capitalization of $5.61 billion, a P/E ratio of 33.04, a price-to-earnings-growth ratio of 1.92 and a beta of 0.66. The company has a debt-to-equity ratio of 1.77, a quick ratio of 1.66 and a current ratio of 2.53.
Integra lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, April 25th. The life sciences company reported $0.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.09. The firm had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $349.15 million. Integra lifesciences had a return on equity of 17.90% and a net margin of 5.39%. Integra lifesciences’s revenue for the quarter was up 38.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.39 earnings per share. equities research analysts predict that Integra lifesciences will post 2.41 earnings per share for the current year.
Integra lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.